New oral drug ABSK021 enters early human testing for Hard-to-Treat cancers
NCT ID NCT04192344
First seen Mar 22, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This early-phase study tests an experimental oral drug called ABSK021 in people with advanced solid tumors (including a rare joint tumor called TGCT) who have run out of standard options. The main goal is to check the drug's safety and find the right dose. Researchers will also watch for any signs that the drug shrinks tumors or slows disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Jishuitan Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact
Contact
-
Hebei Medical University Third Hospital
COMPLETEDShijiazhuang, Hebei, China
-
Henan Cancer Hospital
ACTIVE_NOT_RECRUITINGZhengzhou, Henan, China
-
Huashan Hospital of Fudan University
COMPLETEDShanghai, Shanghai Municipality, China
-
Jiangsu Province Hospital
ACTIVE_NOT_RECRUITINGNanjing, Jiangsu, China
-
Liaoning Cancer Hospital
COMPLETEDShenyang, Liaoning, China
-
MD Anderson Cancer Center
COMPLETEDHouston, Texas, 77030, United States
-
Nanjing Drum Tower Hospital
ACTIVE_NOT_RECRUITINGNanjing, Jiangsu, China
-
Precision NextGen Oncology
ACTIVE_NOT_RECRUITINGBeverly Hills, California, 90212, United States
-
SCRI at HealthOne
COMPLETEDDenver, Colorado, 80218-1238, United States
-
Shanghai Sixth People's Hospital
COMPLETEDShanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangdong, Guangzhou, China
Contact
Contact
-
The First Affiliated Hospital of Zhengzhou Universtity
COMPLETEDZhengzhou, Henan, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact
Contact
-
The Winship Cancer Institute of Emory University
COMPLETEDAtlanta, Georgia, 30322, United States
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact
Contact
-
Xi'an Hong Hui Hospital
RECRUITINGXian, Shanxi, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.